Orquestic regulation of neurotransmitters on reward-seeking behavior

International Archives of Medicine

Volumn 7, Issue 1, 2014, Pages

  Arias Carrión, Oscar ^a,b   Caraza Santiago, Xanic ^a   Salgado Licona, Sergio ^a   Salama, Mohamed ^c   Machado, Sergio ^d,e   Nardi, Antonio Egidio ^d   Menéndez González, Manuel ^f   Murillo Rodríguez, Eric ^g  

^a HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^b Hospital General Ajusco Medio   (Mexico)

^c MANSOURA UNIVERSITY   (Egypt)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e SALGADO DE OLIVEIRA UNIVERSITY   (Brazil)

^f HOSPITAL ÁLVAREZ BUYLLA   (Spain)

^g Universidad del Mayab   (Mexico)

Author keywords

Dopamine; Drug addiction; Endocannabinoids; Galanin; Histamine; Orexin; Reward seeking behavior; Serotonin

Indexed keywords

EID: 84905060321     PISSN: None     EISSN: 17557682     Source Type: Journal    
DOI: 10.1186/1755-7682-7-29     Document Type: Review

References (160)

1. Dopaminergic reward system: a short integrative review. Arias-Carrion O, Stamelou M, Murillo-Rodriguez E, Menendez-Gonzalez M, Poppel E, Int Arch Med 2010 3 24
2. Activity in human ventral striatum locked to errors of reward prediction. Pagnoni G, Zink CF, Montague PR, Berns GS, Nat Neurosci 2002 5 2 97 98 (Pubitemid 34121573)
3. Neural basis of utility estimation. Shizgal P, Curr Opin Neurobiol 1997 7 2 198 208 (Pubitemid 27219856)
4. Prelude to passion: limbic activation by "unseen" drug and sexual cues. Childress AR, Ehrman RN, Wang Z, Li Y, Sciortino N, Hakun J, Jens W, Suh J, Listerud J, Marquez K, Franklin T, Langleben D, Detre J, O'Brien CP, PLoS ONE 2008 3 1 1506
5. Nucleus accumbens cell firing during goal-directed behaviors for cocaine vs. 'natural' reinforcement. Carelli RM, Physiol Behav 2002 76 3 379 387 (Pubitemid 34765591)
6. Distinct subsets of nucleus accumbens neurons encode operant responding for ethanol versus water. Robinson DL, Carelli RM, Eur J Neurosci 2008 28 9 1887 1894
7. Natural rewards, neuroplasticity, and non-drug addictions. Olsen CM, Neuropharmacology 2011 61 7 1109 1122
8. The effect of exposure to drugs on the processing of natural rewards. Anselme P, Neurosci Biobehav Rev 2009 33 3 314 335
9. The neural basis of addiction: a pathology of motivation and choice. Kalivas PW, Volkow ND, Am J Psychiatry 2005 162 8 1403 1413 (Pubitemid 41105554)
10. Role of BDNF and GDNF in drug reward and relapse: a review. Ghitza UE, Zhai H, Wu P, Airavaara M, Shaham Y, Lu L, Neurosci Biobehav Rev 2010 35 2 157 171
11. Phasic dopamine release in appetitive behaviors and drug addiction. Wanat MJ, Willuhn I, Clark JJ, Phillips PE, Curr Drug Abuse Rev 2009 2 2 195 213
12. Shared brain vulnerabilities open the way for nonsubstance addictions: carving addiction at a new joint? Frascella J, Potenza MN, Brown LL, Childress AR, Ann N Y Acad Sci 2010 1187 294 315
13. Neurocircuitry of addiction. Koob GF, Volkow ND, Neuropsychopharmacology 2010 35 1 217 238
14. Kicking the habit: the neural basis of ingrained behaviors in cocaine addiction. Pierce RC, Vanderschuren LJ, Neurosci Biobehav Rev 2010 35 2 212 219
15. The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Russo SJ, Dietz DM, Dumitriu D, Morrison JH, Malenka RC, Nestler EJ, Trends Neurosci 2010 33 6 267 276
16. Cocaine inverts rules for synaptic plasticity of glutamate transmission in the ventral tegmental area. Mameli M, Bellone C, Brown MT, Luscher C, Nat Neurosci 2011 14 4 414 416
17. Review. The incentive sensitization theory of addiction: some current issues. Robinson TE, Berridge KC, Philos T Roy Soc B 2008 363 1507 3137 3146
18. A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine. Avena NM, Hoebel BG, Neuroscience 2003 122 1 17 20 (Pubitemid 37329944)
19. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Koob GF, Le Moal M, Philos T Roy Soc B 2008 363 1507 3113 3123
20. An opponent-process theory of motivation. I. Temporal dynamics of affect. Solomon RL, Corbit JD, Psychol Rev 1974 81 2 119 145
21. The opponent-process theory of acquired motivation: the costs of pleasure and the benefits of pain. Solomon RL, Am Psychol 1980 35 8 691 712
22. Allostasis and addiction: role of the dopamine and corticotropin- releasing factor systems. George O, Le Moal M, Koob GF, Physiol Behav 2012 106 1 58 64
23. The expanding effects of cocaine: studies in a nonhuman primate model of cocaine self-administration. Porrino LJ, Daunais JB, Smith HR, Nader MA, Neurosci Biobehav Rev 2004 27 8 813 820 (Pubitemid 38199611)
24. Goal-directed instrumental action: contingency and incentive learning and their cortical substrates. Balleine BW, Dickinson A, Neuropharmacology 1998 37 4-5 407 419 (Pubitemid 28306930)
25. Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Alcaro A, Huber R, Panksepp J, Brain Res Rev 2007 56 2 283 321 (Pubitemid 350176598)
26. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Ikemoto S, Panksepp J, Brain Res Brain Res Rev 1999 31 1 6 41 (Pubitemid 30009611)
27. Dopamine and reward: the anhedonia hypothesis 30 years on. Wise RA, Neurotox Res 2008 14 2-3 169 183
28. Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory. Ikemoto S, Neurosci Biobehav Rev 2010 35 2 129 150
29. The SEEKING mind: primal neuro-affective substrates for appetitive incentive states and their pathological dynamics in addictions and depression. Alcaro A, Panksepp J, Neurosci Biobehav Rev 2011 35 9 1805 1820
30. Dynamics of neuronal circuits in addiction: reward, antireward, and emotional memory. Koob GF, Pharmacopsychiatry 2009 42 Suppl 1 32 S41
31. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Berridge KC, Robinson TE, Brain Res Brain Res Rev 1998 28 3 309 369 (Pubitemid 29012677)
32. Dopamine, learning, and reward-seeking behavior. Arias-Carrion O, Poppel E, Acta Neurobiol Exp 2007 67 4 481 488
33. A top-down perspective on dopamine, motivation and memory. Phillips AG, Vacca G, Ahn S, Pharmacol Biochem Behav 2008 90 2 236 249 (Pubitemid 351790712)
34. A framework for mesencephalic dopamine systems based on predictive Hebbian learning. Montague PR, Dayan P, Sejnowski TJ, J Neurosci 1996 16 5 1936 1947 (Pubitemid 26145969)
35. Integrating information at single synaptic connections. Montague PR, Proc Natl Acad Sci U S A 1995 92 7 2424 2425
36. Dopamine neuron systems in the brain: an update. Bjorklund A, Dunnett SB, Trends Neurosci 2007 30 5 194 202 (Pubitemid 46654237)
37. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Smith Y, Villalba R, Mov Disord 2008 23 Suppl 3 534 S547
38. High-level levodopa therapy in Parkinson's disease: five years later. Barbeau A, Trans Am Neurol Assoc 1974 99 160 163
39. Electrophysiological studies of neurons in the ventral tegmental area of Tsai. Yim CY, Mogenson GJ, Brain Res 1980 181 2 301 313 (Pubitemid 10130789)
40. BOLD responses reflecting dopaminergic signals in the human ventral tegmental area. D'Ardenne K, McClure SM, Nystrom LE, Cohen JD, Science (New York, NY) 2008 319 5867 1264 1267 (Pubitemid 351323026)
41. Forebrain substrates of reward and motivation. Wise RA, J Comp Neurol 2005 493 1 115 121 (Pubitemid 41636193)
42. Dopamine, learning and motivation. Wise RA, Nat Rev 2004 5 6 483 494 (Pubitemid 38715515)
43. Etiopathogenesis of Parkinson disease: a new beginning? Weidong L, Shen C, Jankovic J, Neuroscientist 2009 15 1 28 35
44. Cholinergic interneuron characteristics and nicotinic properties in the striatum. Zhou FM, Wilson CJ, Dani JA, J Neurobiol 2002 53 4 590 605 (Pubitemid 35375589)
45. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Zhou FM, Wilson C, Dani JA, Neuroscientist 2003 9 1 23 36 (Pubitemid 36139576)
46. Dopamine receptors: from structure to function. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG, Physiol Rev 1998 78 1 189 225 (Pubitemid 28070979)
47. Structure and function of dopamine receptors. Vallone D, Picetti R, Borrelli E, Neurosci Biobehav Rev 2000 24 1 125 132 (Pubitemid 30026154)
48. In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. Saji H, Iida Y, Kawashima H, Ogawa M, Kitamura Y, Mukai T, Shimazu S, Yoneda F, Anal Sci 2003 19 1 67 71
49. Dopamine receptors and brain function. Jaber M, Robinson SW, Missale C, Caron MG, Neuropharmacology 1996 35 11 1503 1519 (Pubitemid 27026480)
50. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Verhoeff NP, Psychopharmacology 1999 147 3 217 249 (Pubitemid 30010543)
51. Neurodegenerative movement disorders: the contribution of functional imaging. Piccini P, Curr Opin Neurol 2004 17 4 459 466 (Pubitemid 39071424)
52. The neurobiology of dopamine signaling. Greengard P, Biosci Rep 2001 21 3 247 269 (Pubitemid 34208249)
53. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Sesack SR, Carr DB, Omelchenko N, Pinto A, Ann N Y Acad Sci 2003 1003 36 52 (Pubitemid 38083044)
54. The ability of the mesocortical dopamine system to operate in distinct temporal modes. Lapish CC, Kroener S, Durstewitz D, Lavin A, Seamans JK, Psychopharmacology 2007 191 3 609 625 (Pubitemid 46355884)
55. Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM, J Neurochem 2003 87 5 1284 1295 (Pubitemid 37485084)
56. Dopamine gating of forebrain neural ensembles. O'Donnell P, Eur J Neurosci 2003 17 3 429 435 (Pubitemid 36255880)
57. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Surmeier DJ, Ding J, Day M, Wang Z, Shen W, Trends Neurosci 2007 30 5 228 235 (Pubitemid 46654239)
58. Prolonged and extrasynaptic excitatory action of dopamine mediated by D1 receptors in the rat striatum in vivo. Gonon F, J Neurosci 1997 17 15 5972 5978 (Pubitemid 27310510)
59. Getting formal with dopamine and reward. Schultz W, Neuron 2002 36 2 241 263 (Pubitemid 35217890)
60. Multiple dopamine functions at different time courses. Schultz W, Annu Rev Neurosci 2007 30 259 288 (Pubitemid 47218758)
61. Behavioral dopamine signals. Schultz W, Trends Neurosci 2007 30 5 203 210 (Pubitemid 46654238)
62. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Di Chiara G, Imperato A, Proc Natl Acad Sci U S A 1988 85 14 5274 5278
63. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. Olive MF, Koenig HN, Nannini MA, Hodge CW, J Neurosci 2001 21 23 C184
64. Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Lin Z, Uhl GR, Mol Pharmacol 2002 61 4 885 891 (Pubitemid 34273169)
65. Trafficking of dopamine transporters in psychostimulant actions. Zahniser NR, Sorkin A, Semin Cell Dev Biol 2009 20 4 411 417
66. Regulation of dopamine transporter trafficking by intracellular amphetamine. Kahlig KM, Lute BJ, Wei Y, Loland CJ, Gether U, Javitch JA, Galli A, Mol Pharmacol 2006 70 2 542 548 (Pubitemid 44092315)
67. Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. Zhu J, Reith ME, CNS Neurol Disord Drug Targets 2008 7 5 393 409
68. Dopamine and the diseased brain. Kienast T, Heinz A, CNS Neurol Disord Drug Targets 2006 5 1 109 131 (Pubitemid 43796630)
69. The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of progress. Kumar S, Porcu P, Werner DF, Matthews DB, Diaz-Granados JL, Helfand RS, Morrow AL, Psychopharmacology 2009 205 4 529 64
70. Low doses of ethanol inhibit the firing of neurons in the substantia nigra, pars reticulata: a GABAergic effect? Mereu G, Gessa GL, Brain Res 1985 360 1-2 325 330 (Pubitemid 16171030)
71. GABAergic mechanisms in regulating the activity state of substantia nigra pars reticulata neurons. Windels F, Kiyatkin EA, Neuroscience 2006 140 4 1289 1299 (Pubitemid 43928290)
72. Disparity between tonic and phasic ethanol-induced dopamine increases in the nucleus accumbens of rats. Robinson DL, Howard EC, McConnell S, Gonzales RA, Wightman RM, Alcohol Clin Exp Res 2009 33 7 1187 96
73. The dopamine response in the nucleus accumbens core-shell border differs from that in the core and shell during operant ethanol self-administration. Howard EC, Schier CJ, Wetzel JS, Gonzales RA, Alcohol Clin Exp Res 2009 33 8 1355 65
74. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Haile CN, Kosten TA, Kosten TR, Am J Drug Alcohol Abuse 2008 34 4 355 381 (Pubitemid 351913747)
75. Pharmacotherapy of addictions. Kreek MJ, LaForge KS, Butelman E, Nat Rev Drug Discov 2002 1 9 710 726 (Pubitemid 37361544)
76. Dopamine depletion reorganizes projections from the nucleus accumbens and ventral pallidum that mediate opioid-induced motor activity. Churchill L, Klitenick MA, Kalivas PW, J Neurosci 1998 18 19 8074 8085 (Pubitemid 28441045)
77. Rats self-administer intravenous nicotine delivered in a novel smoking-relevant procedure: effects of dopamine antagonists. Sorge RE, Clarke PB, J Pharmacol Exp Ther 2009 2009 2009
78. Genetics of dopamine receptors and drug addiction: a comprehensive review. Le Foll B, Gallo A, Le Strat Y, Lu L, Gorwood P, Behav Pharmacol 2009 20 1 1 17
79. Hypothesis that mesolimbic dopamine (DA) plays a key role in mediating the reinforcing effects of drugs of abuse as well as the rewarding effects of ingestive behaviors. Rothman RB, Gendron T, Hitzig P, J Subst Abus Treat 1994 11 3 273 275
80. Role of the ERK/MSK1 signalling pathway in chromatin remodelling and brain responses to drugs of abuse. Brami-Cherrier K, Roze E, Girault JA, Betuing S, Caboche J, J Neurochem 2009 108 6 1323 1335
81. Single dose of morphine produced a prolonged effect on dopamine neuron activities. Zhang D, Zhang H, Jin GZ, Zhang K, Zhen X, Mol Pain 2008 4 57
82. Affective neuroscience of pleasure: reward in humans and animals. Berridge KC, Kringelbach ML, Psychopharmacology 2008 199 3 457 480
83. The debate over dopamine's role in reward: the case for incentive salience. Berridge KC, Psychopharmacology 2007 191 3 391 431 (Pubitemid 46355895)
84. Differential responsiveness to cocaine in C57BL/6J and DBA/2J mice. Rocha BA, Odom LA, Barron BA, Ator R, Wild SA, Forster MJ, Psychopharmacology 1998 138 1 82 88 (Pubitemid 28319051)
85. C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice. McNamara RK, Levant B, Taylor B, Ahlbrand R, Liu Y, Sullivan JR, Stanford K, Richtand NM, Neuroscience 2006 143 1 141 153 (Pubitemid 44667302)
86. Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs. post-withdrawal effects. Belej T, Manji D, Sioutis S, Barros HM, Nobrega JN, Brain Res 1996 736 1-2 287 296 (Pubitemid 26356487)
87. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. Johnson BA, CNS Drugs 2004 18 15 1105 1118 (Pubitemid 40007493)
88. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Johnson BA, Biochem Pharmacol 2008 75 1 34 56 (Pubitemid 350235398)
89. Addiction, compulsive drug seeking, and the role of frontostriatal mechanisms in regulating inhibitory control. Feil J, Sheppard D, Fitzgerald PB, Yucel M, Lubman DI, Bradshaw JL, Neurosci Biobehav Rev 2010 35 2 248 275
90. Functional specificity of ventral striatal compartments in appetitive behaviors. Kelley AE, Ann N Y Acad Sci 1999 877 71 90 (Pubitemid 29351852)
91. Preferential enhancement of dopamine transmission within the nucleus accumbens shell by cocaine is attributable to a direct increase in phasic dopamine release events. Aragona BJ, Cleaveland NA, Stuber GD, Day JJ, Carelli RM, Wightman RM, J Neurosci 2008 28 35 8821 8831
92. The functional divide for primary reinforcement of D-amphetamine lies between the medial and lateral ventral striatum: is the division of the accumbens core, shell, and olfactory tubercle valid? Ikemoto S, Qin M, Liu ZH, J Neurosci 2005 25 20 5061 5065 (Pubitemid 40712850)
93. Positive and negative motivation in nucleus accumbens shell: bivalent rostrocaudal gradients for GABA-elicited eating, taste "liking"/ "disliking" reactions, place preference/avoidance, and fear. Reynolds SM, Berridge KC, J Neurosci 2002 22 16 7308 7320 (Pubitemid 35379185)
94. Cocaine cues drive opposing context-dependent shifts in reward processing and emotional state. Wheeler RA, Aragona BJ, Fuhrmann KA, Jones JL, Day JJ, Cacciapaglia F, Wightman RM, Carelli RM, Biol Psychiatry 2011 69 11 1067 1074
95. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C, J Neurosci 2008 28 2 407 414
96. Kappa opioid receptor activation in the nucleus accumbens inhibits glutamate and GABA release through different mechanisms. Hjelmstad GO, Fields HL, J Neurophysiol 2003 89 5 2389 2395 (Pubitemid 36570203)
97. Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Frankel PS, Alburges ME, Bush L, Hanson GR, Kish SJ, Neuropharmacology 2008 55 1 41 46
98. Is rTMS an effective therapeutic strategy that can be used to treat anxiety disorders? Machado S, Paes F, Velasques B, Teixeira S, Piedade R, Ribeiro P, Nardi AE, Arias-Carrion O, Neuropharmacology 2012 62 1 125 134
99. Early reactions to cannabis predict later dependence. Fergusson DM, Horwood LJ, Lynskey MT, Madden PA, Arch Gen Psychiatry 2003 60 10 1033 1039 (Pubitemid 37222087)
100. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Gifford A, Hitzemann R, Ding YS, Pappas N, Am J Psychiatr 1999 156 9 1440 1443 (Pubitemid 29416545)
101. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A, Neuropsychopharmacology 2002 27 6 1027 1035 (Pubitemid 35447639)
102. The genetic basis of individual differences in reward processing and the link to addictive behavior and social cognition. Yacubian J, Buchel C, Neuroscience 2009 164 1 55 71
103. Neurons containing hypocretin (orexin) project to multiple neuronal systems. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS, J Neurosci 1998 18 23 9996 10015 (Pubitemid 28543775)
104. Reduced number of hypocretin neurons in human narcolepsy. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM, Neuron 2000 27 3 469 474
105. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Sakurai T, Nat Rev 2007 8 3 171 181 (Pubitemid 46294664)
106. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S, Kangawa K, Sakurai T, Yanagisawa M, Nakazato M, Proc Natl Acad Sci U S A 1999 96 2 748 753 (Pubitemid 29061280)
107. Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. van den Pol AN, J Neurosci 1999 19 8 3171 3182 (Pubitemid 29174009)
108. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M, Sakurai T, Brain Res 2000 873 1 181 187 (Pubitemid 30468504)
109. A role for lateral hypothalamic orexin neurons in reward seeking. Harris GC, Wimmer M, Aston-Jones G, Nature 2005 437 7058 556 559 (Pubitemid 41613553)
110. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, de Lecea L, Proc Natl Acad Sci U S A 2005 102 52 19168 19173 (Pubitemid 43049584)
111. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J, Miyatake M, Sakurai T, Yanagisawa M, Nakamachi T, Shioda S, Suzuki T, J Neurosci 2006 26 2 398 405 (Pubitemid 43237102)
112. Implication of protein kinase C in the orexin-induced elevation of extracellular dopamine levels and its rewarding effect. Narita M, Nagumo Y, Miyatake M, Ikegami D, Kurahashi K, Suzuki T, Eur J Neurosci 2007 25 5 1537 1545 (Pubitemid 46568770)
113. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A, Neuron 2006 49 4 589 601 (Pubitemid 43221893)
114. Addiction and arousal: alternative roles of hypothalamic peptides. de Lecea L, Jones BE, Boutrel B, Borgland SL, Nishino S, Bubser M, DiLeone R, J Neurosci 2006 26 41 10372 10375 (Pubitemid 44564586)
115. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, Yanagisawa M, Nestler EJ, DiLeone RJ, J Neurosci 2003 23 8 3106 3111 (Pubitemid 36531950)
116. On the treatment of rapid eye movement narcolepsy. Guilleminault C, Carskadon M, Dement WC, Arch Neurol 1974 30 1 90 93
117. Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity. Cason AM, Smith RJ, Tahsili-Fahadan P, Moorman DE, Sartor GC, Aston-Jones G, Physiol Behav 2010 100 5 419 428
118. Orexin/hypocretin is necessary for context-driven cocaine-seeking. Smith RJ, Tahsili-Fahadan P, Aston-Jones G, Neuropharmacology 2010 58 1 179 184
119. Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. Smith RJ, See RE, Aston-Jones G, Eur J Neurosci 2009 30 3 493 503
120. Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. Richards JK, Simms JA, Steensland P, Taha SA, Borgland SL, Bonci A, Bartlett SE, Psychopharmacology 2008 199 1 109 117
121. Snf1 kinase connects nutritional pathways controlling meiosis in Saccharomyces cerevisiae. Honigberg SM, Lee RH, Mol Cell Biol 1998 18 8 4548 4555 (Pubitemid 28343039)
122. Arousal and reward: a dichotomy in orexin function. Harris GC, Aston-Jones G, Trends Neurosci 2006 29 10 571 577 (Pubitemid 44416459)
123. Fos expression in orexin neurons varies with behavioral state. Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, Saper CB, Scammell TE, J Neurosci 2001 21 5 1656 1662 (Pubitemid 32182206)
124. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. Fadel J, Bubser M, Deutch AY, J Neurosci 2002 22 15 6742 6746 (Pubitemid 35386430)
125. Hypocretin/orexin and nociceptin/orphanin FQ coordinately regulate analgesia in a mouse model of stress-induced analgesia. Xie X, Wisor JP, Hara J, Crowder TL, LeWinter R, Khroyan TV, Yamanaka A, Diano S, Horvath TL, Sakurai T, Toll L, Kilduff TS, J Clin Invest 2008 118 7 2471 2481 (Pubitemid 351949775)
126. Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: Focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin. Martin-Fardon R, Zorrilla EP, Ciccocioppo R, Weiss F, Brain Res 2010 1314 145 161
127. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. Lester DB, Rogers TD, Blaha CD, CNS Neurosci Ther 2010 16 3 137 162
128. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC, Neurobiol Dis 2008 30 1 74 83
129. Histamine in the nervous system. Haas HL, Sergeeva OA, Selbach O, Physiol Rev 2008 88 3 1183 1241
130. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Pillot C, Heron A, Cochois V, Tardivel-Lacombe J, Ligneau X, Schwartz JC, Arrang JM, Neuroscience 2002 114 1 173 193 (Pubitemid 35247499)
131. Histamine responses of large neostriatal interneurons in histamine H1 and H2 receptor knock-out mice. Ogawa S, Yanai K, Watanabe T, Wang ZM, Akaike H, Ito Y, Akaike N, Brain Res Bull 2009 78 4-5 189 194
132. Involvement of the brain histaminergic system in addiction and addiction-related behaviors: a comprehensive review with emphasis on the potential therapeutic use of histaminergic compounds in drug dependence. Brabant C, Alleva L, Quertemont E, Tirelli E, Prog Neurobiol 2010 92 3 421 441
133. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL, Biochem Biophys Res Commun 2001 280 1 132 138 (Pubitemid 32923047)
134. Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Holst B, Schwartz TW, Trends Pharmacol Sci 2004 25 3 113 117 (Pubitemid 38264498)
135. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Bowers CY, Momany FA, Reynolds GA, Hong A, Endocrinology 1984 114 5 1537 1545 (Pubitemid 14140300)
136. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E, Elsworth JD, Roth RH, Sleeman MW, Picciotto MR, Tschop MH, Gao XB, Horvath TL, J Clin Invest 2006 116 12 3229 3239 (Pubitemid 44878637)
137. Blockade of central nicotine acetylcholine receptor signaling attenuate ghrelin-induced food intake in rodents. Dickson SL, Hrabovszky E, Hansson C, Jerlhag E, Alvarez-Crespo M, Skibicka KP, Molnar CS, Liposits Z, Engel JA, Egecioglu E, Neuroscience 2010 171 4 1180 1186
138. Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Jiang H, Betancourt L, Smith RG, Mol Endocrinol 2006 20 8 1772 1785 (Pubitemid 44148083)
139. The alcohol-induced locomotor stimulation and accumbal dopamine release is suppressed in ghrelin knockout mice. Jerlhag E, Landgren S, Egecioglu E, Dickson SL, Engel JA, Alcohol 2011 45 4 341 347
140. Requirement of central ghrelin signaling for alcohol reward. Jerlhag E, Egecioglu E, Landgren S, Salome N, Heilig M, Moechars D, Datta R, Perrissoud D, Dickson SL, Engel JA, Proc Natl Acad Sci U S A 2009 106 27 11318 11323
141. Ghrelin receptor antagonism attenuates cocaine- and amphetamine-induced locomotor stimulation, accumbal dopamine release, and conditioned place preference. Jerlhag E, Egecioglu E, Dickson SL, Engel JA, Psychopharmacology 2010 211 4 415 422
142. Ghrelin increases intake of rewarding food in rodents. Egecioglu E, Jerlhag E, Salome N, Skibicka KP, Haage D, Bohlooly YM, Andersson D, Bjursell M, Perrissoud D, Engel JA, Dickson SL, Addict Biol 2010 15 3 304 311
143. Galanin-a novel biologically active peptide from porcine intestine. Tatemoto K, Rokaeus A, Jornvall H, McDonald TJ, Mutt V, FEBS Lett 1983 164 1 124 128 (Pubitemid 14201839)
144. Galanin and spinal pain mechanisms: where do we stand in 2008? Xu XJ, Hokfelt T, Wiesenfeld-Hallin Z, Cell Mol Life Sci 2008 65 12 1813 1819
145. Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. Kolakowski LF Jr, O'Neill GP, Howard AD, Broussard SR, Sullivan KA, Feighner SD, Sawzdargo M, Nguyen T, Kargman S, Shiao LL, Hreniuk DL, Tan CP, Evans J, Abramovitz M, Chateauneuf A, Coulombe N, Ng G, Johnson MP, Tharian A, Khoshbouei H, George SR, Smith RG, O'Dowd BF, J Neurochem 1998 71 6 2239 2251 (Pubitemid 28531233)
146. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Lang R, Gundlach AL, Kofler B, Pharmacol Ther 2007 115 2 177 207 (Pubitemid 47042915)
147. Galanin and galanin-like peptide modulate neurite outgrowth via protein kinase C-mediated activation of extracellular signal-related kinase. Hawes JJ, Narasimhaiah R, Picciotto MR, Eur J Neurosci 2006 23 11 2937 2946 (Pubitemid 43882873)
148. Effects of galanin on dopamine release in the central nervous system of normotensive and spontaneously hypertensive rats. Tsuda K, Tsuda S, Nishio I, Masuyama Y, Goldstein M, Am J Hypertens 1998 11 12 1475 1479 (Pubitemid 29030313)
149. Suggestive evidence for inhibitory effects of galanin on mesolimbic dopaminergic neurotransmission. Ericson E, Ahlenius S, Brain Res 1999 822 1-2 200 209 (Pubitemid 29222843)
150. Testing the hypothesis that locus coeruleus hyperactivity produces depression-related changes via galanin. Weiss JM, Boss-Williams KA, Moore JP, Demetrikopoulos MK, Ritchie JC, West CH, Neuropeptides 2005 39 3 281 287 (Pubitemid 40804598)
151. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Holmes A, Kinney JW, Wrenn CC, Li Q, Yang RJ, Ma L, Vishwanath J, Saavedra MC, Innerfield CE, Jacoby AS, Shine J, Iismaa TP, Crawley JN, Neuropsychopharmacology 2003 28 6 1031 1044
152. Centrally administered galanin blocks morphine place preference in the mouse. Zachariou V, Parikh K, Picciotto MR, Brain Res 1999 831 1-2 33 42 (Pubitemid 29336185)
153. Galanin protects against behavioral and neurochemical correlates of opiate reward. Hawes JJ, Brunzell DH, Narasimhaiah R, Langel U, Wynick D, Picciotto MR, Neuropsychopharmacology 2008 33 8 1864 1873 (Pubitemid 351832595)
154. Mu-opioid receptor activation induces transcriptional plasticity in the central extended amygdala. Befort K, Filliol D, Ghate A, Darcq E, Matifas A, Muller J, Lardenois A, Thibault C, Dembele D, Le Merrer J, Becker JA, Poch O, Kieffer BL, Eur J Neurosci 2008 27 11 2973 2984 (Pubitemid 351832223)
155. Upregulation of galanin binding sites and GalR1 mRNA levels in the mouse locus coeruleus following chronic morphine treatments and precipitated morphine withdrawal. Zachariou V, Thome J, Parikh K, Picciotto MR, Neuropsychopharmacology 2000 23 2 127 137 (Pubitemid 30406897)
156. Genetic susceptibility to heroin addiction: a candidate gene association study. Levran O, Londono D, O'Hara K, Nielsen DA, Peles E, Rotrosen J, Casadonte P, Linzy S, Randesi M, Ott J, Adelson M, Kreek MJ, Genes Brain Behav 2008 7 7 720 729
157. Effects of galanin on cocaine-mediated conditioned place preference and ERK signaling in mice. Narasimhaiah R, Kamens HM, Picciotto MR, Psychopharmacology 2009 204 1 95 102
158. Behavioural characterisation of young adult transgenic mice overexpressing galanin under the PDGF-B promoter. Kuteeva E, Hokfelt T, Ogren SO, Regul Pept 2005 125 1-3 67 78 (Pubitemid 39593710)
159. Orexigenic peptides and alcohol intake: differential effects of orexin, galanin, and ghrelin. Schneider ER, Rada P, Darby RD, Leibowitz SF, Hoebel BG, Alcohol Clin Exp Res 2007 31 11 1858 1865 (Pubitemid 47609647)
160. Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors. Picciotto MR, Brabant C, Einstein EB, Kamens HM, Neugebauer NM, Brain Res 2010 1314 206 218